Cargando…

Orexin-A Levels in Relation to the Risk of Metabolic Syndrome in Patients with Schizophrenia Taking Antipsychotics

BACKGROUND: The role of orexin-A in regulating metabolic homeostasis has been recognized, but its association with antipsychotic-induced metabolic abnormalities remains unclear. We investigated the association between orexin-A levels and metabolic syndrome in patients with schizophrenia treated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Po-Yu, Chen, Chun-Hsin, Chang, Chin-Kuo, Kao, Chung-Feng, Lu, Mong-Liang, Lin, Shih-Ku, Huang, Ming-Chyi, Hwang, Ling-Ling, Mondelli, Valeria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Regular Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313111/ https://www.ncbi.nlm.nih.gov/pubmed/30204875 http://dx.doi.org/10.1093/ijnp/pyy075

Ejemplares similares

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

Positive Symptoms in Antipsychotic-naïve Schizophrenia are Associated with Increased Body Mass Index after Treatment
por: Lin, Shih-Hsien, et al.
Publicado: (2021)

Orexin Modulation of VTA Dopamine Neuron Activity: Relevance to Schizophrenia
por: Perez, Stephanie M, et al.
Publicado: (2021)

Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study
por: Chiu, Chih-Chiang, et al.
Publicado: (2016)

Correction: Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study
por: Chiu, Chih-Chiang, et al.
Publicado: (2018)

Outpatient Antipsychotic Treatment and Inpatient Costs of Schizophrenia
por: Marcus, Steven C., et al.
Publicado: (2008)

Volume alteration of hippocampal subfields in first-episode antipsychotic-naïve schizophrenia patients before and after acute antipsychotic treatment
por: Li, Wenbin, et al.
Publicado: (2018)

Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia
por: Lieslehto, Johannes, et al.
Publicado: (2022)

Alterations of Intrinsic Connectivity Networks in Antipsychotic-Naïve First-Episode Schizophrenia
por: Anhøj, Simon, et al.
Publicado: (2018)

Identification of Susceptible Loci and Enriched Pathways for Bipolar II Disorder Using Genome-Wide Association Studies
por: Kao, Chung-Feng, et al.
Publicado: (2016)

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2008)

The effect of duration of illness and antipsychotics on subcortical volumes in schizophrenia: Analysis of 778 subjects
por: Hashimoto, Naoki, et al.
Publicado: (2017)

Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2020)

Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia
por: Itahashi, Takashi, et al.
Publicado: (2021)

Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review
por: Sentissi, Othman, et al.
Publicado: (2008)

Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2022)

A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics
por: Gilca, Marilena, et al.
Publicado: (2014)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

PM379. Quality of Life in patients with schizophrenia or bipolar disorder receiving long-acting antipsychotics
por: Lin, Shih-Ku
Publicado: (2016)

Metabolic Disturbances Independent of Body Mass in Patients with Schizophrenia Taking Atypical Antipsychotics
por: Kang, Shi Hyun, et al.
Publicado: (2015)

Cardiac structure and function in patients with schizophrenia taking antipsychotic drugs: an MRI study
por: Pillinger, Toby, et al.
Publicado: (2019)

Polymorphisms in Schizophrenia-Related Genes Are Potential Predictors of Antipsychotic Treatment Resistance and Refractoriness
por: Zazueta, Alejandra, et al.
Publicado: (2022)

Corpus callosum volumes in the 5 years following the first-episode of schizophrenia: Effects of antipsychotics, chronicity and maturation
por: de Moura, Mariana T.M., et al.
Publicado: (2018)

Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up
por: Taipale, Heidi, et al.
Publicado: (2018)

Differential Co-Occurring Patterns Between Depressive Symptomatology and Sleep-Wake-Related Disturbances in Mood Disorders
por: Chen, Sze-Yu, et al.
Publicado: (2021)

Associations of Genetic Variants of Methylenetetrahydrofolate Reductase and Serum Folate Levels with Metabolic Parameters in Patients with Schizophrenia
por: Chen, Chun-Hsin, et al.
Publicado: (2021)

Attenuated mismatch negativity in patients with first-episode antipsychotic-naive schizophrenia using a source-resolved method
por: Randau, M., et al.
Publicado: (2019)

National database study on the use of long‐acting antipsychotic injections and hospital readmission proportions in patients with schizophrenia in Japan
por: Usuki, Masato, et al.
Publicado: (2020)

Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia
por: Kubota, Manabu, et al.
Publicado: (2017)

T213. TREND OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS USE IN ASIA: FINDINGS FROM REAP ANTIPSYCHOTIC STUDIES
por: Lin, Shih-Ku, et al.
Publicado: (2020)

Detection of advanced brain aging in schizophrenia and its structural underpinning by using normative brain age metrics
por: Chen, Chang-Le, et al.
Publicado: (2022)

Schizophrenia Patients Discharged on Clozapine Plus Long-Acting Injectable Antipsychotics From a Public Psychiatric Hospital in Taiwan, 2006–2021
por: Lin, Ta-Chun, et al.
Publicado: (2023)

Antidepressive Effect of Antipsychotics in the Treatment of Schizophrenia: Meta-Regression Analysis of Randomized Placebo-Controlled Trials
por: Miura, Itaru, et al.
Publicado: (2020)

Antipsychotic medications and stroke in schizophrenia: A case-crossover study
por: Chen, Wen-Yin, et al.
Publicado: (2017)

Housing First Improves Adherence to Antipsychotic Medication Among Formerly Homeless Adults With Schizophrenia: Results of a Randomized Controlled Trial
por: Rezansoff, Stefanie N., et al.
Publicado: (2017)

Two Neuroanatomical Signatures in Schizophrenia: Expression Strengths Over the First 2 Years of Treatment and Their Relationships to Neurodevelopmental Compromise and Antipsychotic Treatment
por: du Plessis, Stefan, et al.
Publicado: (2023)

Role of the orexin 2 receptor in palatable-food consumption-associated cardiovascular reactivity in spontaneously hypertensive rats
por: Huang, Shang-Cheng, et al.
Publicado: (2018)

Fatty Acid Desaturase Gene Polymorphisms and Metabolic Measures in Schizophrenia and Bipolar Patients Taking Antipsychotics
por: Burghardt, Kyle J., et al.
Publicado: (2013)

Sex Differences in Demand for Highly Palatable Foods: Role of the Orexin System
por: Freeman, Linnea R, et al.
Publicado: (2020)

Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia
por: Hopkins, Seth C, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2r7983lu7s833rsqqsjac4ba6g